Index Fund Advisors Inc. Increases Stock Position in Johnson & Johnson (NYSE:JNJ)

Index Fund Advisors Inc. grew its position in Johnson & Johnson (NYSE:JNJGet Rating) by 8.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,499 shares of the company’s stock after purchasing an additional 755 shares during the period. Johnson & Johnson comprises about 0.1% of Index Fund Advisors Inc.’s portfolio, making the stock its 22nd largest position. Index Fund Advisors Inc.’s holdings in Johnson & Johnson were worth $1,552,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in JNJ. Morton Brown Family Wealth LLC increased its holdings in Johnson & Johnson by 78.0% during the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after buying an additional 78 shares during the last quarter. Goodman Advisory Group LLC bought a new position in Johnson & Johnson during the second quarter worth about $39,000. Cardinal Capital Management Inc. boosted its position in Johnson & Johnson by 333.3% during the second quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock worth $46,000 after purchasing an additional 200 shares during the period. First Bank & Trust boosted its position in shares of Johnson & Johnson by 69.6% in the second quarter. First Bank & Trust now owns 380 shares of the company’s stock valued at $67,000 after acquiring an additional 156 shares during the period. Finally, Heritage Wealth Management LLC bought a new position in shares of Johnson & Johnson in the second quarter valued at approximately $84,000. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Peter Fasolo sold 22,864 shares of the business’s stock in a transaction dated Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total value of $3,761,128.00. Following the completion of the transaction, the vice president now owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion of the transaction, the vice president now directly owns 40,133 shares in the company, valued at approximately $6,869,966.94. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Peter Fasolo sold 22,864 shares of the business’s stock in a transaction that occurred on Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total value of $3,761,128.00. Following the transaction, the vice president now owns 114,676 shares of the company’s stock, valued at $18,864,202. The disclosure for this sale can be found here. In the last 90 days, insiders sold 300,750 shares of company stock valued at $52,311,677. 0.35% of the stock is owned by insiders.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $173.43 on Monday. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The stock has a market cap of $453.43 billion, a PE ratio of 24.15, a price-to-earnings-growth ratio of 3.28 and a beta of 0.56. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. The company’s fifty day moving average price is $176.32 and its 200-day moving average price is $171.47.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. The firm had revenue of $23.79 billion for the quarter, compared to analysts’ expectations of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The company’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.60 EPS. On average, equities analysts expect that Johnson & Johnson will post 10.04 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be given a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.61%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is 62.95%.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Raymond James cut their price objective on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. Sanford C. Bernstein lowered their target price on shares of Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. StockNews.com started coverage on shares of Johnson & Johnson in a research note on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Credit Suisse Group started coverage on shares of Johnson & Johnson in a research note on Thursday, November 17th. They issued a “neutral” rating and a $170.00 target price on the stock. Finally, Citigroup raised their target price on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research note on Monday, December 12th. Seven investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $182.42.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.